Intra-Cellular Therapies Inc (NASDAQ: ITCI) stock closed at $94.87 on 1/10/25 after a major increase of 14.9%. Moreover, exceptionally high trading volume at 687% of normal accompanied the advance. Relative to the market the stock has been strong over the last nine months and has risen 13.6% during the last week.
Current PriceTarget Research Rating
Intra-Cellular Therapies has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Intra-Cellular Therapies has a very low Appreciation Score of 9 but a slightly positive Power Rating of 65, resulting in the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment